SH2 domain-containing inositol 5-phosphatase (SHIP2) inhibition ameliorates high glucose-induced de-novo lipogenesis and VLDL production through regulating AMPK/mTOR/SREBP1 pathway and ROS production in HepG2 cells - PubMed (original) (raw)
SH2 domain-containing inositol 5-phosphatase (SHIP2) inhibition ameliorates high glucose-induced de-novo lipogenesis and VLDL production through regulating AMPK/mTOR/SREBP1 pathway and ROS production in HepG2 cells
Sattar Gorgani-Firuzjaee et al. Free Radic Biol Med. 2015 Dec.
Abstract
Hepatic de-novo lipogenesis and production of triglyceride rich very low density lipoprotein (VLDL) is increased in the state of insulin resistance, however, the role of a negative regulator of the insulin signaling pathway, the SH2 domain-containing inositol 5-phosphatase (SHIP2) in this process, remains unknown. In the present study, we studied the molecular mechanisms linking SHIP2 expression to metabolic dyslipidemia using overexpression or suppression of SHIP2 gene in HepG2 cells exposed to high glucose (33 mM). The results showed that high glucose induced SHIP2 mRNA and protein levels in HepG2 cells. Overexpression of the dominant negative mutant SHIP2 (SHIP2-DN) ameliorated high glucose-induced de-novo lipogenesis and secretion of apoB containing lipoprotein in HepG2 cells, as demonstrated by a reduction in both secreted apoB and MTP expression, and decreased triglyceride levels and the expression of lipogenic genes such as SREBP1c, FAS and ACC. Overexpression of the SHIP2-DN decreased high glucose-induced apoB containing lipoproteins secretion via reduction in ROS generation, JNK phosphorylation and Akt activation. Furthermore, using the specific inhibitor and activator, it was found that the AMPK/mTOR/SREBP1 is the signaling pathway that mediates the effects of SHIP2 modulation on hepatic de-novo lipogenesis. Taken together, these findings suggest that SHIP2 is an important regulator of hepatic lipogenesis and lipoprotein secretion in insulin resistance state.
Keywords: De-novo lipogenesis; HepG2; Hyperglycemia; Insulin resistance; Liver; SH2 domain containing inositol 5-phosphatase (SHIP2); VLDL.
Copyright © 2015 Elsevier Inc. All rights reserved.
Similar articles
- SH2 domain-containing inositol 5-phosphatase (SHIP2) regulates de-novo lipogenesis and secretion of apoB100 containing lipoproteins in HepG2 cells.
Gorgani-Firuzjaee S, Khatami S, Adeli K, Meshkani R. Gorgani-Firuzjaee S, et al. Biochem Biophys Res Commun. 2015 Sep 4;464(4):1028-1033. doi: 10.1016/j.bbrc.2015.07.059. Epub 2015 Jul 17. Biochem Biophys Res Commun. 2015. PMID: 26188518 - Inhibition of SH2-domain-containing inositol 5-phosphatase (SHIP2) ameliorates palmitate induced-apoptosis through regulating Akt/FOXO1 pathway and ROS production in HepG2 cells.
Gorgani-Firuzjaee S, Adeli K, Meshkani R. Gorgani-Firuzjaee S, et al. Biochem Biophys Res Commun. 2015 Aug 21;464(2):441-6. doi: 10.1016/j.bbrc.2015.06.134. Epub 2015 Jun 26. Biochem Biophys Res Commun. 2015. PMID: 26123392 - Impact of the liver-specific expression of SHIP2 (SH2-containing inositol 5'-phosphatase 2) on insulin signaling and glucose metabolism in mice.
Fukui K, Wada T, Kagawa S, Nagira K, Ikubo M, Ishihara H, Kobayashi M, Sasaoka T. Fukui K, et al. Diabetes. 2005 Jul;54(7):1958-67. doi: 10.2337/diabetes.54.7.1958. Diabetes. 2005. PMID: 15983195 - Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity.
Sasaoka T, Wada T, Tsuneki H. Sasaoka T, et al. Pharmacol Ther. 2006 Dec;112(3):799-809. doi: 10.1016/j.pharmthera.2006.06.001. Epub 2006 Jul 13. Pharmacol Ther. 2006. PMID: 16842857 Review. - The SH2 domain containing inositol polyphosphate 5-phosphatase-2: SHIP2.
Dyson JM, Kong AM, Wiradjaja F, Astle MV, Gurung R, Mitchell CA. Dyson JM, et al. Int J Biochem Cell Biol. 2005 Nov;37(11):2260-5. doi: 10.1016/j.biocel.2005.05.003. Int J Biochem Cell Biol. 2005. PMID: 15964236 Review.
Cited by
- Effects of HIIT training and HIIT combined with circuit resistance training on measures of physical fitness, miRNA expression, and metabolic risk factors in overweight/obese middle-aged women.
Pashaei Z, Malandish A, Alipour S, Jafari A, Laher I, Hackney AC, Suzuki K, Granacher U, Saeidi A, Zouhal H. Pashaei Z, et al. BMC Sports Sci Med Rehabil. 2024 May 29;16(1):123. doi: 10.1186/s13102-024-00904-7. BMC Sports Sci Med Rehabil. 2024. PMID: 38812051 Free PMC article. - Alkylphthalides with intracellular triglyceride metabolism-promoting activity from the rhizomes of Cnidium officinale Makino.
Morikawa T, Inoue N, Yamamoto S, Shiotani M, Manse Y, Ninomiya K. Morikawa T, et al. J Nat Med. 2024 Jun;78(3):709-721. doi: 10.1007/s11418-024-01799-x. Epub 2024 Apr 4. J Nat Med. 2024. PMID: 38575838 - Melatonin targets ferroptosis through bimodal alteration of redox environment and cellular pathways in NAFLD model.
Saha M, Das S, Manna K, Saha KD. Saha M, et al. Biosci Rep. 2023 Oct 31;43(10):BSR20230128. doi: 10.1042/BSR20230128. Biosci Rep. 2023. PMID: 37728565 Free PMC article. - O-GlycNacylation Remission Retards the Progression of Non-Alcoholic Fatty Liver Disease.
Zhou Y, Li Z, Xu M, Zhang D, Ling J, Yu P, Shen Y. Zhou Y, et al. Cells. 2022 Nov 16;11(22):3637. doi: 10.3390/cells11223637. Cells. 2022. PMID: 36429065 Free PMC article. Review. - Chlorogenic acid improves anti-lipogenic activity of metformin by positive regulating of AMPK signaling in HepG2 cells.
Namvarjah F, Shokri-Afra H, Moradi-Sardareh H, Khorzoughi RB, Pasalar P, Panahi G, Meshkani R. Namvarjah F, et al. Cell Biochem Biophys. 2022 Sep;80(3):537-545. doi: 10.1007/s12013-022-01077-1. Epub 2022 Jun 15. Cell Biochem Biophys. 2022. PMID: 35704155
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous